Profound Medical Sees Impressive Revenue Growth in 2024

Profound Medical Reports Strong Revenue Growth for 2024

Profound Medical Corp. (NASDAQ: PROF; TSX: PRN), a leader in innovative medical device solutions, has announced impressive preliminary unaudited revenues for the fourth quarter and full year of 2024.

Unveiling Fourth Quarter Performance

As the year winds to a close, Profound estimates its fourth quarter revenues will reach between $4.1 million and $4.2 million. This marks a remarkable year-over-year growth of approximately 105% to 110%, showcasing the company's robust market expansion. Moreover, the sequential growth from the previous quarter is expected to fall between 45% and 48%. For the entire year of 2024, total revenues are projected to be in the range of $11.1 million to $11.2 million, a substantial increase compared to around $7.2 million from the prior year.

Investment Community Engagement

Profound's impressive revenue projections come as the company prepares for significant engagements with the investment community. Notably, they are scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference, convening in San Francisco. The event, slated for January 16, offers a pivotal opportunity for the company to share its achievements and future aspirations with investors.

Transition to U.S. GAAP Reporting

Effective January 1, 2025, Profound will shift its financial reporting practices to align with U.S. generally accepted accounting principles (GAAP). This strategic move will also see the company filing with the U.S. Securities and Exchange Commission (SEC) using domestic forms, which is expected to greatly enhance transparency and facilitate easier access to financial information for U.S.-based investors.

CEO Insights on Growth and Strategy

Reflecting on the company's performance, CEO Arun Menawat expressed optimism regarding the trajectory of the TULSA-PRO platform—a leading-edge treatment for prostate disease. He emphasized that, following the recent completion of a significant public offering, Profound is well-positioned to leverage increasing reimbursement opportunities and expand its market presence.

Innovative Medical Solutions from Profound

Profound Medical's flagship technology, TULSA-PRO®, utilizes real-time MRI and advanced ultrasound techniques to provide a minimally invasive treatment option for prostate conditions. This innovative approach not only preserves patients' urinary continence and sexual function but also demonstrates efficacy across various prostate disease spectrums.

Expanding Horizons with Sonalleve

In addition to TULSA-PRO®, Profound is also advancing its Sonalleve® platform, designed for treating uterine fibroids and bone metastases. The CE marked device has gained significant attention and regulatory approval, highlighting Profound's dedication to addressing significant health challenges with innovative health technologies.

Future Paths and Community Engagement

As Profound transitions into 2025, the company aims to build on its momentum within the investment community and further illustrates the importance of its technological innovations. With ongoing educational efforts and regulatory advancements, Profound is set to enhance its visibility and appeal among investors.

Engaging successfully with stakeholders is critical to Profound's strategy, ensuring that investors understand the company's objectives and the potential for future growth.

Frequently Asked Questions

What revenue growth did Profound Medical report for 2024?

Profound Medical reported an estimated fourth quarter revenue growth of 105% to 110% year-over-year.

What changes is Profound Medical making regarding its financial reporting?

Profound will begin reporting in accordance with U.S. GAAP and filing with the SEC starting January 1, 2025.

When is Profound Medical presenting at the JPM conference?

Profound Medical is scheduled to present on January 16, at 11:15 a.m. PT during the JPM 2025 conference.

What technologies does Profound Medical specialize in?

Profound specializes in TULSA-PRO®, a treatment for prostate disease and Sonalleve®, targeted towards uterine fibroids and pain management.

How has Profound Medical performed in terms of revenue?

The company anticipates total revenue for 2024 to be approximately $11.1 million to $11.2 million, reflecting significant growth from the previous year.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.